PMID- 1709503
OWN - NLM
STAT- MEDLINE
DCOM- 19910614
LR  - 20200930
IS  - 0037-9727 (Print)
IS  - 0037-9727 (Linking)
VI  - 197
IP  - 2
DP  - 1991 Jun
TI  - In vivo administration of tumor necrosis factor-alpha is associated with 
      antiviral activity in human peripheral mononuclear cells.
PG  - 144-9
AB  - Tumor necrosis factor-alpha (TNF-alpha) has a spectrum of biologic effects and 
      has been shown to exert antiviral effects in fibroblasts in vitro. The in vivo 
      administration of TNF-alpha (40-160 micrograms/m2 intravenously over 2 hr) and 
      its effects on vesicular stomatitis virus (VSV) replication in peripheral blood 
      mononuclear cells (PBMC) from patients with malignancy was investigated. Blood 
      was obtained before, during, and after infusion. The PBMC were separated and 
      infected with VSV at a multiplicity of infection of 0.005 plaque-forming 
      units/cell and virus yields were determined 72 h later. The TNF-alpha inhibited 
      VSV yields by as much as 99% in a dose-dependent manner with the inhibition 
      initially observed during the first hour of infusion. Despite a rapid reduction 
      in TNF-alpha serum levels, the higher doses still produced antiviral effects 4 hr 
      after the infusion. Sera obtained at identical times had no interferon activity. 
      Human gamma-interferon (25 micrograms/ml) added in vitro augmented the 
      TNF-alpha-induced inhibitory activity in both magnitude and duration. Percentages 
      of lymphocytes and monocytes in peripheral blood were reduced at 4 hr after 
      TNF-alpha administration and the monocyte to lymphocyte ratio was diminished and 
      temporally coincided with the loss of TNF-induced antiviral state. These data 
      suggest that the in vivo administration of TNF has a direct inhibitory activity 
      on VSV replication in human peripheral blood mononuclear cells that was 
      enhanceable by gamma-interferon and possibly monocyte mediated.
FAU - Nokta, M
AU  - Nokta M
AD  - Department of Internal Medicine, University of Texas Medical Branch, Galveston 
      77550.
FAU - Matzke, D
AU  - Matzke D
FAU - Jennings, M
AU  - Jennings M
FAU - Schlick, E
AU  - Schlick E
FAU - Nadler, P I
AU  - Nadler PI
FAU - Pollard, R
AU  - Pollard R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Proc Soc Exp Biol Med
JT  - Proceedings of the Society for Experimental Biology and Medicine. Society for 
      Experimental Biology and Medicine (New York, N.Y.)
JID - 7505892
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 9008-11-1 (Interferons)
SB  - IM
MH  - Cells, Cultured
MH  - Dose-Response Relationship, Drug
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Interferons/blood/pharmacology
MH  - Leukocytes, Mononuclear/*microbiology
MH  - Lymphocytes/cytology
MH  - Male
MH  - Middle Aged
MH  - Monocytes/cytology
MH  - Neoplasms/*blood
MH  - Radioimmunoassay
MH  - Tumor Necrosis Factor-alpha/administration & 
      dosage/pharmacokinetics/*pharmacology
MH  - Vesicular stomatitis Indiana virus/*drug effects/physiology
MH  - Virus Replication/*drug effects
EDAT- 1991/06/01 00:00
MHDA- 1991/06/01 00:01
CRDT- 1991/06/01 00:00
PHST- 1991/06/01 00:00 [pubmed]
PHST- 1991/06/01 00:01 [medline]
PHST- 1991/06/01 00:00 [entrez]
AID - 10.3181/00379727-197-43236 [doi]
PST - ppublish
SO  - Proc Soc Exp Biol Med. 1991 Jun;197(2):144-9. doi: 10.3181/00379727-197-43236.